Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.70 |
| ▸ | BRAF | P15056 | 8/20 | 0.70 |
| ▸ | RIPK3 | Q9Y572 | 7/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.56 |
| ▸ | TEK | Q02763 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454632 | 0.93 | BRAF (0.70) | KDRBRAFRIPK3RIPK1 | |
| SCHEMBL2452555 | 0.91 | KDR (0.71) | KDRBRAFRIPK3RIPK1TEK | |
| SCHEMBL2457139 | 0.89 | BRAF (0.65) | KDRBRAFRIPK3RIPK1 | |
| SCHEMBL2452667 | 0.89 | BRAF (0.65) | KDRBRAFRIPK3RIPK1TEK | |
| SCHEMBL2455836 | 0.88 | KDR (0.68) | KDRBRAFRIPK3RIPK1 | |
| SCHEMBL2453065 | 0.87 | BRAF (0.67) | KDRBRAFRIPK3RIPK1TEK | |
| SCHEMBL2452470 | 0.87 | BRAF (0.69) | KDRBRAFRIPK3RIPK1 | |
| SCHEMBL2457228 | 0.86 | KDR (0.61) | KDRBRAFRIPK3RIPK1TEK | |
| SCHEMBL2851381 | 0.84 | BRAF (0.77) | KDRBRAFRIPK3RIPK1 | |
| SCHEMBL2452584 | 0.84 | RIPK1 (0.64) | KDRBRAFRIPK3RIPK1TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399921-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-8697874-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-15 | — | — | US | disclosed |
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NR3C2, RAF1 | KDR 432/4885BRAF 1/4885RIPK3 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.